Global Blood Transfusion Diagnostics Information, by product (Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations, others) by Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test, others) by end user (Hospitals, Clinics, Blood banks, Laboratories) - Forecast till 2023
Various factors are propelling the blood transfusion diagnostics market growth. These factors, as per the new Market Research Future (MRFR) report, include government schemes for paid and voluntary blood donation, huge patient population suffering from chronic diseases especially leukemia, sickle cell anemia, and aplastic anemia, increasing awareness about automation of blood banks and blood transfusions, and strict regulations pertaining to the use as well as transfer of blood. Additional factors pushing market growth include demand for screened blood products, availability of different blood transfusion procedures, and increasing incidence of infectious diseases.
“Blood transfusion laboratory is an essential part of providing healthcare services to the patients. Blood and blood products like RBC’s, WBC’s, platelets and others are transfused from one person to another. This requires screening tests which are vital before conducting blood transfusion. Strict regulation governing the use and transfer of blood, increasing awareness regarding blood transfusion and automation of blood banks drive the growth of this market. Risk involved in blood transfusion is transmission of infectious disease from one person to another without carrying out screening procedure. ”
Blood Transfusion Diagnostics Market Share is expected to reach USD 2.45 billion by 2023 at a CAGR of 8.2% during the forecast period from 2017-2023.
Major players in this market are: Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S), Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).
Depending on geographic region, blood transfusion diagnostics market is segmented into four key regions: Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for blood transfusion diagnostics. Increasing adoption of nucleic acid implication test of diagnosis, automation of blood banks and strict rules pertaining to storage & transfusion of blood drive the growth of this market in North America. Enormous non-government organization working for cancer patients conduct camps and awareness programs for safe handling of blood. The European market is also growing continuously and slowly catching up with the American market in the near future. Demand for improved diagnostics test, available skilled healthcare professionals and collaboration of NGO’s with government bodies boost the growth of this market in Europe. Asia Pacific market is expected to show fastest growth in the blood transfusion diagnostics market during the forecasted period. Japan is the largest market in Asia Pacific. Increasing penetration of market leaders in Asia Pacific, demand out reaching supplies, demand for new technology adoption and increasing number of donors contribute to the growth of this market in Asia Pacific. Middle East & Africa show steady growth in this market.
Market Research Future (MRFR) recognizes the following companies as the key players in Blood Transfusion Diagnostics Market: There are plenty of large and small market players which operate in this market all over the globe.
The MRFR report provides an all-inclusive segmental analysis of the blood transfusion diagnostics market on the basis of blood product, technology, and end users.
Based on the blood product, the blood transfusion diagnostics market is segmented into immunoglobulin preparations, albumin, plasma, platelets, red blood cells, and other products.
By technology, the global blood transfusion diagnostics market is segmented into rapid test, fluorescence assay, nucleic acid amplification, ELISA, western blot, and other technologies. The ELISA segment is again segmented into colorimetric immunoassay (CI), fluorescence immunoassays (FIA), and chemiluminescence immunoassay. The nucleic acid amplification segment is again segmented into real-time PCR and thermomechanical analysis (TMA).
Based on end users, the blood transfusion diagnostics market is segmented into laboratories, blood banks, clinics, and hospitals. Of these, the blood banks segment will dominate the market over the forecast period chiefly due to the increase in the number of blood centers and blood banks worldwide.